Design and synthesis of 3,7-diarylimidazopyridines as inhibitors of the VEGF-receptor KDR

Bioorganic and Medicinal Chemistry Letters

Volumn 14, Issue 4, 2004, Pages 909-912

  Wu, Zhicai ^a   Fraley, Mark E ^a   Bilodeau, Mark T ^a   Kaufman, Mildred L ^a   Tasber, Edward S ^a   Balitza, Adrienne E ^a   Hartman, George D ^a   Coll, Kathleen E ^a   Rickert, Keith ^a   Shipman, Jennifer ^a   Shi, Bin ^a   Sepp Lorenzino, Laura ^a   Thomas, Kenneth A ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMIDAZOPYRIDINE DERIVATIVE; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; VASCULOTROPIN RECEPTOR;

AQUEOUS SOLUTION; ARTICLE; DRUG DESIGN; DRUG SOLUBILITY; DRUG SYNTHESIS; ENZYME ACTIVITY; ENZYME INHIBITION; STRUCTURE ACTIVITY RELATION;

EID: 10744233313     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2003.12.007     Document Type: Article

References (20)

1. Adamis A.P., Shima D.T., Yeo K.T., Yeo T.K., Brown L.F., Berse B., D'Amore P.A., Folkman J. Biochem. Biophys. Res. Commun. 193:1993;631.
2. Giatromanolaki A., Sivridis E., Athanassou N., Zois E., Thorpe P.E., Brekken R.A., Gatter K.C., Harris A.L., Koukourakis I.M., Koukourakis M.I. J. Path. 194:2001;101.
3. Detmar M. Dermatol. Sci. 24:2000;S78.
4. For reviews, see: Carmeliet P., Jain R.K. Nature. 407:2000;249.
5. Folkman J. Nature Med. 1:1995;27.
6. Veikkola T., Karkkainen M., Claesson-Welsh L., Alitalo K. Cancer Res. 60:2000;203.
7. Thomas K.A. J. Biol. Chem. 271:1996;603.
8. Lin Y.S., Nguyen C., Mendoza J.L. J. Pharm. Exp. Ther. 188:1999;371.
9. Lu D., Jimenez X., Zhang H., Bohlen P., Witte L., Zhu Z. Int. J. Cancer. 97:2002;393.
10. Holash J., Davis S., Papadopoulos N., Croll S.D., Ho L., Russell M., Boland P., Leidich R., Hylton D., Burova E., Ioffe E., Huang T., Radziejewski C., Bailey K., Fandl J.P., Daly T., Wiegand S.J., Yancopoulos G.D., Rudge J.S. Proc. Natl. Acad. Sci. U.S.A. 99:2002;11393.
11. For recent reviews, see: Bilodeau M.T., Fraley M.E., Hartman G.D. Expert Opin. Investig. Drugs. 11:2002;737.
12. Boyer S.J. Curr. Top. Med. Chem. 2:2002;973.
13. Yang J.C., Haworth L., Sherry R.M., Hwu P., Schwartzentruber D.J., Topalian S.L., Steinberg S.M., Chen H.X., Rosenberg S.A. N. Engl. J. Med. 349:2003;427.
14. Fraley M.E., Hoffman W.F., Rubino R.S., Hungate R.W., Tebben A.J., Rutledge R.Z., McFall R.C., Huckle W.R., Kendall R.L., Coll K.E., Thomas K.A. Bioorg. Med. Chem. Lett. 12:2002;2767.
15. Fraley M.E., Rubino R.S., Hoffman W.F., Hambaugh S.R., Arrington K.L., Hungate R.W., Bilodeau M.T., Tebben A.J., Rutledge R.Z., Kendall R.L., McFall R.C., Huckle W.R., Coll K.E., Thomas K.A. Bioorg. Med. Chem. Lett. 12:2002;3537.
16. Bilodeau M.T., Cunningham A.M., Koester T.J., Ciecko P.A., Coll K.E., Huckle W.R., Hungate R.W., Kendall R.L., McFall R.C., Mao X., Rutledge R.Z., Thomas K.A. Bioorg. Med. Chem. Lett. 13:2003;2485.
17. 1H NMR and mass spectroscopy.
18. 50 value represents biochemical inhibition of phosphorylation of a poly-Glu/Tyr (4:1) peptide substrate by isolated KDR kinase (cloned and expressed as a GST-fusion protein), see: Kendall R.L., Rutledge R.Z., Mao X., Tebben A.L., Hungate R.W., Thomas K.A. J. Biol. Chem. 274:1999;6453. Values are reported as single determinations or as the average of at least two determinations±standard deviation.
19. Compounds 10f and 10g were prepared similarly according to the following Scheme:
20. Traxler P., Furet P. Pharmacol. Ther. 82:1999;195.